TOG Review (RCOG Journal)
MRCOG Part 2
Urogynaecology and Pelvic Floor Problems
The use of urethral bulking agents in the treatment of stress urinary incontinence
Key Statistics
- 25% — UI prevalence, women ≥20y (n≈28,000)
- 32% — Overall bulking agent complication rate
- 12–35% — Bulkamid® patients needing reinjection
Don't-miss facts
-
Bulking agents are NOT first-line SUI treatment (Cochrane 2017) – offer only after conservative management fails and after full counselling on alternatives
-
Counsel that bulking agents are permanent materials, efficacy is inferior to other surgery, durability is poor, and repeat injection is often needed (12–35% for Bulkamid®)
-
TVT beats Bulkamid® on both subjective (99% vs 85%) and objective (95% vs 66%) cure, but with more complications
-
Overall complication rate 32% (mostly minor/transient); 3% major, needing further procedure
-
Fatal PE reported after autologous fat migration – halted its use as a bulking agent
-
National mesh pause since July 2018 – retropubic MUT remains an option but counsel as permanent implant with possible incomplete removal
-
NICE 2019: local MDT for any invasive SUI procedure; regional MDT for repeat surgery, mesh complications, or future pregnancy plans
-
Bulking agents are technically easier to learn → risk of widespread adoption ahead of long-term safety/efficacy data, echoing lessons from mesh
Agents at a glance
Current UK: Bulkamid® · Macroplastique® · Durasphere® · Coaptite® · Urolastic®
Withdrawn: bovine collagen (Contigen®, 2011) · autologous fat (fatal PE)
Abbreviation Key
- UI — urinary incontinence
- BMI — body mass index
- SUI — stress urinary incontinence
- MUT — mid-urethral tape
- MUI — mixed urinary incontinence
- TVT — tension-free vaginal tape
- UUI — urgency urinary incontinence
- MDT — multidisciplinary team
- ISD — intrinsic sphincter deficiency
- PROMS — patient reported outcome measures
- NICE — National Institute for Health and Care Excellence
- COPD — chronic obstructive pulmonary disease
- PFMT — pelvic floor muscle training
- IGF-1 — insulin-like growth factor 1
Source: McGowan S, Campbell P, Dolan L. The use of urethral bulking agents in the treatment of stress urinary incontinence. The Obstetrician & Gynaecologist 2020;22:137–146. doi:10.1111/tog.12647
MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG).